how long have glp 1 been on the market Upgrading from Overweight: Effects of GLP-1 Drugs the Investment Landscape GLP-1 Market Size, Scope, Forecast

In TRIUMPH-4, it affected 8.8% of the 9mg group and 20.9% of the 12mg group, compared to just 0.7% on placebo

Diamond MP, Reece EA, Caprio S, et al

*Correspondence: Elisabet Jerlhag, [email protected] This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

This situation feels different from other drug classes because it is: diabetes and obesity are massive markets, and beyond the FDA approved indicated populations, theres a swath of people interested in getting their hands on GLP-1 agonists off-label to help them lose a few extra pounds

Thway K, Fisher C

Specifically, patients taking 2.4mg of Wegovy lost up to 17% of their weight over 68 weeks of treatment, while patients taking CagriSema lost up to 22.7% of their body weight in a Phase 3 clinical trial